Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials. (linkinghub.elsevier.com)

Authors: Hauser SL … Kappos L Journal: The Lancet Published: 2026-05-30 DOI: https://doi.org/10.1016/S0140-6736(26)00147-9